– The authors have reviewed literature regarding the main contributions of molecular biology to renal cell carcinoma characterisation. The progress made in the analysis of chromosomal alterations, oncogenes, p53 protein, proliferation indices and adhesion molecules are described. The authors conclude that molecular biology, especially the analysis of chromosomal alterations and proliferation indices, may contribute to renal cell carcinoma diagnosis and to the understanding of its pathogenesis and prognosis.
LatifF., ToryK., GnarraJ.: Identification of the von Hippel-Lindau disease tumour suppression gene. Science, 260: 1317–20, 1993.
2.
KovacsG.: The value of molecular genetics analysis in the diagnosis and prognosis of renal cell carcinoma. World J. Urol., 12: 64–8, 1994.
3.
YoshidaK., TosakaA., TakeuchiS., KobayashiN.: Epidermal growth factor receptor content in human renal cell carcinoma. Cancer, 73: 1913–8, 1994.
4.
ZoonKC., KarasakiY., Zur NeddenD.L, HuR., HarnheiterH.: Modulation of epidermal growth factor receptors by human alpha interferon. Proc. Natl Acad. Sci. USA, 83: 8226–30, 1986.
5.
WeidnerU., PeterS., StrohmeyerT., HussnätterR., AckermannR., SiesH.: Inverse relationship of epidermal growth factor receptor and HER2/neu gene expression in human renal cell carcinoma. Cancer Res., 50: 4504, 1990.
6.
RotterM., BlockT., BuschR., ThannerS., HöflerH.: Expression of HER-2/neu in renal cell carcinoma. Correlation with histologic subtypes and differenziation. Int. J. Cancer, 52: 213, 1992.
7.
DanovaM., GiordanoM., TorelliF., FranchiniG., CappellanoF., RiccardiA., CatanzaroF., MazziniG.: HER-2/neu oncogene expression and DNA ploidy in normal human kidney and renal cell carcinoma. Eur. J. Histochem., 36: 279–288, 1992.
8.
HiseM.K., JacobsS.C., PapadimitriouJ.C., Dra-chembergC.I.: Transforming growth factor-alpha expression in human renal cell carcinoma: TGF–α in renal cell carcinoma. Urology, 47 (1): 29–33, 1996.
9.
NanusD.M., Schmitz-DragerB.J., MotzerR.J., LeeA.C., VlamisV., Cordon-CardoC., AlbinoA.P., ReuterV.E.: Expression of basic fibroblastic growth factor in primary human renal tumours: correlation with poor survival. J. Natl Cancer Inst., 85: 1597–9, 1993.
10.
StrohmeyerT.G., SlamonD.J.: Proto-oncogenes and tumour suppressor genes in human urological malignancies. J. Urol., 151: 1479–1497, 1994.
11.
ImaiS., KiyozukaY., NishimuraH., IwanagaS., MurakamiF., ImamuraK, NodaT., HagaS., YakushijiM.: Overexpression of the tumour suppressor gene p53 in human ovarian tumour tissues and its correlation with clinical stage. Int. J. Oncol., 4: 1097–1103, 1994.
12.
MaruyamaL., ShiozakiH., ShimayaK., InoueM., IwazawaT., MatsuiS., MoriT.: p53 expression in esophageal dysplasia: a possible biomarker of esophageal squamous cell carcinoma. Int. J. Oncol., 4: 1061–5, 1994.
13.
MonicaB., MinariR.: Indici di proliferazione (Ki-67, TLI) ed espressione della p53. Esperienza personale. Urologia, 62 (2): 234–9, 1995.
14.
PavelicZ.P., GluckmanJ.L., GapanyM. e Coll.: Improved immunohistochemical detection of p53 protein in paraffin embedded tissues reveals elevated levels in most head and neck and lung carcinomas: correlation with clinico-pathological parameters. Anticancer Res., 12: 1389–94, 1992.
15.
SoiniY., Turpeenniemi-HujuanenT., KamelD., Autio-HarmainenH., RisteliH., RisteliL., NuorvaK., PääkköP., VäkäkangasK.: p53 immunohistochemistry in transitional cell carcinoma and dysplasia of the urinary bladder correlates with disease progression. Br. J. Cancer, 68: 1029–35, 1993.
16.
Van den BergF.M., TiggesA.J., SchipperM.E.I., den Hartog-JagerF.C.A., KroesW.G.M., WalboomersJ.M.M.: Expression of the nuclear oncogene p53 in colon tumours. J. Pathol. (Lond.), 157: 193–9, 1989.
17.
ReiterE., AnglardP., LiuS., GnarraJ.R., LinehanW. M.: Chromosome 17p deletions and p53 mutations in renal cell carcinoma. Cancer Res., 53: 3092–7, 1993.
18.
AnglardP., ToryK., BrauchH., WeissG.H., LatifF., MerinoM.J., LermanM.I., ZbarB., LinehanW.M.: Molecular analysis of genetic changes in the origin and development of renal cell carcinoma. Cancer Res., 51: 1071–7, 1991.
19.
SuzukiY., TamuraG., SatodateR., FujiokaT.: Infrequent mutation of p53 gene in human renal cell carcinoma detected by polimerase chain reaction-single strand conformational polymorphism analysis. Jpn. J. Cancer Res., 83: 233–5, 1992.
20.
OkaK., IshikawaJ., BrunerJ.M., TakahashiR., SayaH.: Detection of loss of heterozygosity in the p53 gene in renal cell carcinoma and bladder cancer using the polimerase chain reaction. Mol. Carcinnog., 4: 10–3, 1991.
21.
ZbarB.BrauchH., TalmadgeC., LinehanM.: Loss of alleles loci on the short arm of chromosome 3 in renal cell carcinoma. Nature (Lond.), 327: 721–7, 1987.
22.
ChemerisG., LoktinovA., RempelA., SchwartzM., BannaschP.: Elevated content of p53 protein in absence of p53 gene mutation as a possible marker for human renal cell tumours. Virchows Arch., 426: 563–9, 1995.
23.
ImaiY., StrohmeyerT.G., FleischhackerM., SlamonD. J., KoefflerP.: p53 mutation and MDM-2 amplification in renal cell cancer. Modern Pathology, 7 (7): 766–70, 1994.
24.
KikukiY., KishiT., SuzukiM., FurusatoM., AizawaS.: Polimerase chain reaction-single strand conformational polymorfism analysis of the p53 gene in paraffin embedded surgical material from human renal cell carcinonma. Virchows Arch., 424: 229–33, 1994.
UchidaT., WadaC., ShitaraT., EgawaS., MashimoS., KoshibaK.: Infrequent involvement of p53 mutation and loss of heterozygosity of 17p in the tumorigenesis of renal cell carcinoma. J. Urol., 150: 1298–1301, 1993.
27.
CozzoliA.ManteroG.L., VerardiR.MagaliniA.R., GarzaL., BerenziA., CoscianiCunico S., AlbertiniA.: Valutazione di p53 nel carcinoma renale mediante citometria a flusso ed analisi molecolare. Acta Urol. Ital., (suppl.) 2: 249–50, 1993.
28.
OdaH., NakatsuruY., IshikawaT.: Mutation of the p53 gene and p53 protein overexpression are associated with sarcomatoid transformation in renal cell carcinorna. Cancer Res., 55: 658–62, 1995.
29.
KamelD., Turpeenniemi-HujuanenT., VähäkangasK., PääkköP., SoiniY.: Proliferating cell nuclear antigen, but not p53 or human papillomavirus DNA correlates with advanced clinical stage in renal cell carcinoma. Hystopathology, 25: 339–47, 1994.
30.
TomasinoR.M., MorelloV., TralongoV., NagarC., NuaraR., DanieleE., CurtiM., OrestanoF.: p53 expression in human renal cell carcinoma: an immunohi-stochemical study and a literature outline of the cytogenetic characterization. Pathologica, 86: 227–33, 1994.
31.
BotF.J., GodschalkJ.C.J., KrishnadathK.K., van der KwastT.H.M., BosmanF.: Prognostic factors in renal cell carcinoma: immunohistochemical detection of p53 protein versus clinico-pathological parameters. Int. J. Cancer, 57: 634–7, 1994.
32.
UhlmanD.L., NguyenP.L., ManivelJ.C., AeppliD., ResnickJ.M., FraleyE.E., ZhangG., NiehansG.: Association of immunohistochemical staining for p53 with metastatic progression and poor survival in patients with renal cell carcinoma. J. Natl. Can. Inst., 86 (19): 1470–5, 1994.
33.
deRieseW.T.W., CrabtreeW.N., AllhoffE.P., WernerM., LiedkeS., LenisG., AtzpodienJ., KirchnerH.: Prognostic significance of Ki-67 immunostaining in non-metastatic renal cell carcinoma. J. Clin. Oncol., 11: 1804–8, 1993.
34.
ShimazuiT., TomobeM., HattoriK., UchidaK., AkazaH., KoisoK.: A prognostic significance of nucleolar organiser region (AgNOR) in renal cell carcinoma. J. Urol., 154: 1522–26, 1995.
KatagiriA., WatanabeR., TornitaY.: E-cadherin expression in renal cell cancer and its significance in metastases and survival. Br. J. Cancer, 71: 376–9, 1995.
37.
TerpeH., TajrobebkarK., GüntherU., AltmannsbergerM.: Expression of cell adhesion molecules alpha-2, alpha-5, alpha-6 integrin, E-cadherin, N-CAM and CD-44 in renal cell carcinomas. Virchows Archiv. Pathol. Anat., 422: 219–24, 1993.
38.
ShimazuiT., BringuierP.P., GiroldiL., OosterwijkE., DebruyneF.M.J., SchalkenJ.A: Identification and characterization of cadherin-catenin complexes in renal cell carcinoma cell line. J. Urol., 155 (suppl.): 344A, (abstract 135), 1996.
